Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Hepatitis C (HCV) is a disease that affects the liver. ITX 5061 is a new medication that is
being tested to treat HCV. This study will evaluate the safety of ITX 5061 and examine
different doses of the medication to evaluate which dose is the most effective at lowering
the amount of HCV in the blood.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)